(Corrects paragraph 8 of Dec. 17 story to reflect that the EU regulator reversed its July decision in November to recommend approval for Biogen's drug, Leqembi) (Reuters) -China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's,

China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there almost a year after Eisai and Biogen's anti-amyloid rival Leqembi (lecanemab), which was cleared by the NMPA in January.

Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion),

China has approved Eli Lillys Kisunla, marking another milestone in global efforts to address Alzheimers disease. The treatment, designed to slow memory decline and clear brain plaques, offers early-stage patients a

The summary highlights significant activities in the health sector, including Eli Lilly's Alzheimer's treatment approval in China, Merck's deal with Hansoh for a new obesity drug, impending HIV medication availability,

China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option after Eisai and Biogen's Leqembi received approval in January, the company said late on Tuesday.